How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Quiescent B Cells for immune suppression in gene therapy

Organization name

ascenion GmbH

Profile

Challenge

B cells are well-known for their roles in humoral immunity. Recently, a novel role for B cells as potent immunosuppressive cells in vivo has been described. In order to make clinical use of these suppressive features of B cells to suppress immune reactions against auto-antigens, therapeutic proteins, gene therapy products and grafts, methods are required to re-design resting B cells into antigen-specific immune suppressive B cells while keeping them in a non-stimulatory state.

Technology

The technology relates to engineering resting B cells into “resting regulatory B cells” combining the weak immunogenicity of quiescent cells, and the suppressive and antigen-presentation features of activated B cells. This is accomplished with a lentiviral vector allowing expression of any desired antigen in native B cells. After transformation, B cells remain quiescent, as demonstrated by lack of IL-6 secretion and of activation-marker expression. Such engineered B cells inhibit specific CD4 T, CD8 T, and B cells in recipient mice and induce complete remission from Experimental Autoimmune Encephalomyelitis (EAE) immune disorder in mice upon adoptive transfer.

The method described is fast and easily applicable, effectively proven to work in mice and potentially suitable for the treatment of several different immune disorders. The technology is expected to be beneficial for the treatment of autoimmune diseases, should reduce adverse immune reactions in graft-versus-host diseases, and should prevent immune reactions against protein drugs in biologics and gene therapy.

Commercial Opportunity

In-licensing for the clinical development; collaboration opportunity.

Patent Situation

A European Patent Application (EP 10075225) has been filed (unpublished).

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries